We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Novel Formulation of Chlorhexidine Spheres and Sustained Release with Multilayered Encapsulation.
ACS Applied Materials & Interfaces 2016 May 26
This work demonstrates the synthesis of new chlorhexidine polymorphs with controlled morphology and symmetry, which were used as a template for layer-by-layer (LbL) encapsulation. LbL self-assembly of oppositely charged polyelectrolytes onto the drug surface was used in the current work, as an efficient method to produce a carrier with high drug content, improved drug solubility and sustained release. Coprecipitation of the chlorhexidine polymorphs was performed using chlorhexidine diacetate and calcium chloride solutions. Porous interconnected chlorhexidine spheres were produced by tuning the concentration of calcium chloride. The size of these drug colloids could be further controlled from 5.6 μm to over 20 μm (diameter) by adjusting the coprecipitation temperature. The chlorhexidine content in the spheres was determined to be as high as 90%. These particles were further stabilized by depositing 3.5 bilayers of poly(allylamine hydrochloride) (PAH) and polystyrenesulfonate (PSS) on the surface. In vitro release kinetics of chlorhexidine capsules showed that the multilayer shells could prolong the release, which was further demonstrated by characterizing the remaining chlorhexidine capsules with SEM and confocal microscopy. The new chlorhexidine polymorph and LbL coating has created novel chlorhexidine formulations. Further modification to the chlorhexidine polymorph structure is possible to achieve both sustained and stimuli responsive release, which will enhance its clinical performance in medicine and dentistry.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app